Bazedoxifene analogs as potential WDHD1 degraders and antitumor agents: Synthesis, evaluation and molecular dynamics simulation studies

• Published in: Drug development research 2024-02, Vol.85 (1), p.e22155-n/a
• Main Authors: Chen, Leyuan, Liu, Gaiting, Meng, Fancui, shi, Yu, Fang, Zhennan, Peng, Zhenyu, Wang, Manjiang, Gou, Wenfeng, Hou, Wenbin, Li, Yiliang
• Format: Article
• Language: English
• Subjects: Analogs; Anticancer properties; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Antitumor agents; bazedoxifene; Chemical synthesis; Chemotherapy; degraders; Deoxyribonucleic acid; DNA; DNA repair; DNA-Binding Proteins; drug discovery; Homologous recombination; Homologous recombination repair; Humans; Indoles - pharmacology; Indoles - therapeutic use; MCF-7 Cells; Molecular dynamics; Molecular Dynamics Simulation; Radiation therapy; Tumors; United States; WDHD1 (AND‐1)
• ISSN: 0272-4391; 1098-2299
• DOI: 10.1002/ddr.22155

DNA repair is strongly associated with tumor resistance to radiotherapy and chemotherapy. WD repeat and HMG‐box DNA binding protein 1 (WDHD1) is a key adaptor for homologous recombination repair of DNA, and its overexpression is relevant to the poor prognosis of many tumor patients. We previously have identified and validated bazedoxifene (BZA), which had 60% inhibitory rate on WDHD1 in MCF7 cells at 10 μM, from the Food and Drug Administration‐approved compound library. Here, we initially established the binding model of BZA, synthesized and evaluated eight BZA analogs. Further, we detailed the use of molecular dynamics simulations to provide insights into the basis for activity against WDHD1. This binding mode will be instructive for the development of new WDHD1 degraders.